Product Description: Goflikicept (RPH 104) is a hybrid protein that selectively binds and inactivates both circulating IL-1ß and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI)[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Samsonov M, et al. Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale. J Transl Med. 2021 Apr 26;19(1):169.
CAS Number: 2416984-26-2
Molecular Weight: N/A
Compound Purity: 98.32
Research Area: Inflammation/Immunology; Cardiovascular Disease